Treatments for proliferative vitreoretinopathy

A vitreoretinal and proliferative technology, applied in sensory diseases, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as the unknown role of TAK1

Inactive Publication Date: 2016-06-29
MOR RES APPL LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, the role of TAK1 in RPE cell signal transd

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatments for proliferative vitreoretinopathy
  • Treatments for proliferative vitreoretinopathy
  • Treatments for proliferative vitreoretinopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Example 1: TGF-β1 activates TAK1MAP kinase in RPE cells

[0092] TAK1 is a known mediator of TGF-β1 signaling, but was not detected (inactive or active form) in RPE cells. This example shows that TAK1 is expressed and activated in RPE cells.

[0093] To study the kinetics and expression pattern of activated TAK1 in RPE cells upon TGF-β1 treatment, RPE cells were immunostained with a phospho-TAK1 antibody that specifically recognizes the activated form of TAK1 phosphorylated on Thr187 . Such as figure 1 As shown, TAK1 activation, which can be observed in non-nuclear staining, gradually increases in treated cells, peaks at 24 hours after treatment and then decreases. In contrast, control cells showed only critical levels of activated TAK1 without significant changes, thus demonstrating specific activation of TAK1 by TGF-β1 in RPE cells.

[0094] Abnormal expression and activity of TAK1 in diseased retina and RPE cells Figure 6A , Figure 6B (retina), Figure 7A an...

Embodiment 2

[0095] Example 2: Inhibition of TAK1 in RPE cells stops the EMT process under TGF-β1 stimulation

[0096] EMT is known to be mediated by various factors. This example shows that TGF-β1-stimulated EMT that occurs in RPE can be mediated by activated TAK1.

[0097] EMT of RPE cells is known to be mediated through TGF-β1 and is characterized by increased expression of α-SMA, enhanced cell migration and secretion of MMPs. To address the possible involvement of TAK1 in the differentiation and transformation of RPE cells induced by TGF-β1, the effect of specific TAK1 inhibitors on this process was investigated. The key step in the differentiation of RPE cells into myofibroblasts is the de novo synthesis of α-SMA (Hinz et al., AmJ Pathol 2001, 159:1009-1020). In order to observe this process in vitro, RPE cells were stimulated with TGF-β1 for 2 days in the presence or absence of TAK1 inhibitor (5Z-7-oxozeaenol) under serum-free conditions, or with DMSO as a control group ( Figure ...

Embodiment 3

[0103] Example 3: TAK1 regulates TGF-β signal transduction in RPE cells

[0104] The results shown in Example 2 indicate that inhibition of TAK1 reduces α-SMA expression and cell migration. These processes are known to be regulated by TGF-β1 signaling through Smad2 / 3 in RPE cells (MuY et al., Cell Tissue Res 2011, 347:11-20). This example explores whether TAK1 inhibition has an effect on the phosphorylation of Smad2 / 3.

[0105] RPE cells were treated with or without 5Z-7-oxozeaenol, followed by TGF-β1, and the phosphorylation pattern of Smad2 / 3 was examined by immunoblotting. Phospho-Smad2 / 3 was observed to increase immediately and reach maximum activation at 60 minutes in TGF-β1-treated cells ( Figure 4A ). In contrast, Smad2 / 3 activation was barely detectable in cells pretreated with 5Z-7-oxozeaenol. Calculation of the ratio of phosphorylated-Smad2 / 3 to total Smad2 / 3 at each time point clearly demonstrated that inhibition of TAK1 activity abolished Smad2 / 3 activation in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein are methods for treatment for proliferative vitreoretinopathy (PVR) by inhibiting the activity of activated transforming growth factor Beta activated kinase 1 (TAK-1), or activation thereof. Pharmaceutical compositions for use in the described treatments are also provided.

Description

[0001] Cross References to Related Applications [0002] The benefit of U.S. Provisional Patent Application No. 61 / 887,747, filed October 7, 2013 is claimed; which is hereby incorporated by reference in its entirety. technical field [0003] Provided herein are methods for treating proliferative vitreoretinopathy (PVR) by inhibiting the activity of transforming growth factor beta-activated kinase 1 (TAK-1). Also provided are pharmaceutical compositions for use in said treatment. Background technique [0004] Proliferative vitreoretinopathy (PVR) is a scarring process that develops as a complication in retinal detachment (RD), and it is the most common cause of surgical failure in the treatment of RD (Ho et al., Br J Ophthalmol 1985, 69:584-587 ). PVR is a dynamic process characterized by the formation of fibrotic tissue on the detached retina preventing reattachment of the retina and may eventually cause blindness (Lambert et al., Seminarsinophthalmology 1995, 10:49-52). ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/335A61P27/02
CPCA61K31/335A61P27/02
Inventor 阿亚拉·波拉克泽埃夫·德瓦施
Owner MOR RES APPL LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap